While many solid cancers display upregulation of BCLxL or MCL-1 compared to the respective healthy cells (reviewed in [11]), a basal upregulation of cellular BCL2A1 levels has been described in breast cancer, melanoma, or hematological and lymphoid cancers, such as DLBCL [9]. The gene discussed is BCL2A1; the disease is lymphoma.